One of the applications Idevax is working on is in therapeutic drug delivery in the field of Cancer Vaccines and Immunotherapy, and Cell-and gen-based therapîes:

Therapeutic cancer vaccines:

Bacillus Calmette-Guérin (BCG) vaccine is commonly linked to prevention of Tuberculosis, but is also used to treat bladder cancer. Also, a dendritic cell-based vaccine (Sipuleucel-T) is commercially available for castration-resistant prostate cancer. Additionally, several therapeutic cancer vaccines are in development or in the preclinical or clinical research phase.

Cell- and gene-based therapies:
Therapeutic drug delivery can also be used to treat auto-immune diseases like Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA) using cell-based therapy. Indeed, intradermal administration of autologous dendritic cells to treat auto-immune diseases such as MS is being investigated. However, for the treatment to be effective, it is important that viable and functional cells are not damaged by shear stress and reach the site of action without change in cell phenotype.

Idevax has an ongoing collaboration with the University of Antwerp (BE), University Hospital of Antwerp (BE) and anicells (BE). The consortium is working on intradermal delivery of tolerogenic DC-based therapy to treat MS.

Click here to know more!